Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

UDIT NARAIN VERMA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1033178165
CMS profile
1104572
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$19.68

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $19.68 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $19.68 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

UDIT NARAIN VERMA

NPI 1033178165 · CMS profile ID 1104572

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033178165?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
UDIT NARAIN VERMA, NPI 1033178165, CMS profile ID 1104572. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033178165?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). UDIT NARAIN VERMA, NPI 1033178165, CMS profile ID 1104572. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033178165?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
UDIT NARAIN VERMA, NPI 1033178165, CMS profile ID 1104572, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1033178165?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $19.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $19.6803/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190594821 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,479.75 8
PY2021 $366.18 2
PY2022 $116.79 2
PY2024 $2,020.00 2
PY2025 $19.68 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $91,962.90 72
PY2020 Principal investigator $39,950.14 23
PY2019 Principal investigator $52,486.64 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $4,615.00 12/03/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749616345
Principal investigator 1 EMD Serono, Inc. $1,950.00 11/18/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749610397
Principal investigator 1 EMD Serono, Inc. $65.00 11/16/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749587693
Principal investigator 1 EMD Serono, Inc. $65.00 11/16/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749587695
Principal investigator 1 EMD Serono, Inc. $65.00 11/16/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749587699
Principal investigator 1 EMD Serono, Inc. $65.00 11/16/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749587703
Principal investigator 1 EMD Serono, Inc. $207.30 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749594995
Principal investigator 1 EMD Serono, Inc. $325.00 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749594997
Principal investigator 1 EMD Serono, Inc. $325.00 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749595001
Principal investigator 1 EMD Serono, Inc. $325.00 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749595005
Principal investigator 1 EMD Serono, Inc. $325.00 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749595007
Principal investigator 1 EMD Serono, Inc. $325.00 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749595011
Principal investigator 1 EMD Serono, Inc. $325.00 11/05/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749595015
Principal investigator 1 EMD Serono, Inc. $6,350.00 09/09/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749616913
Principal investigator 1 EMD Serono, Inc. $4,030.00 04/01/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749616159
Principal investigator 1 EMD Serono, Inc. $1,950.00 03/02/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749610389
Principal investigator 1 EMD Serono, Inc. $121.00 02/13/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749591387
Principal investigator 1 EMD Serono, Inc. $1,056.00 02/13/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749604687
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,178.00 01/13/2020 Non-covered Recipient Entity
UNIVERSITY TEXAS SOUTHWESTERN MEDICAL CENTER
A RANDOMIZED DOUBLE BLIND MULTICENTER PHASE III STUDY OF EVEROLIMUS RAD001 PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN THE TREATMENT OF PATIENTS WITH ADVANCED NET OF GI OR LUNG ORIGIN No dispute reported 06/30/2026 721497317
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,487.84 01/07/2020 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A RANDOMIZED DOUBLE BLIND MULTICENTER PHASE III STUDY OF EVEROLIMUS RAD001 PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN THE TREATMENT OF PATIENTS WITH ADVANCED NET OF GI OR LUNG ORIGIN No dispute reported 06/30/2026 721497249
Principal investigator 1 EMD Serono, Inc. $1,500.00 01/02/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749607987
Principal investigator 1 EMD Serono, Inc. $1,500.00 01/02/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749607991
Principal investigator 1 EMD Serono, Inc. $2,795.00 01/02/2020 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 749613657